185057-00-5

Basic information

• Product Name: METHYL 1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBOXYLATE
• Synonyms: METHYL 1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBOXYLATE;1,2,3,4-tetrahydroisoquinoline-6-carboxylate hydrochloride;6-Isoquinolinecarboxylicacid, 1,2,3,4-tetrahydro-, Methyl ester;1,2,3,4-Tetrahydroisoquinoline-6-carboxylic acid methyl ester;1,2,3,4-tetrahydroisoquinoline-6-carboxylate
• CAS NO: 185057-00-5
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.22642
• Mol File: 185057-00-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 330.2 °C at 760 mmHg
• Flash Point: 153.5 °C
• Appearance: /
• Density: 1.123 g/cm³
• Storage Temp.: 2-8°C
• PKA: 8.74±0.20(Predicted)
• CAS DataBase Reference: METHYL 1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBOXYLATE(185057-00-5)
• EPA Substance Registry System: METHYL 1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBOXYLATE(185057-00-5)

Safety Data

• Statements: 25-36/37/38
• Safety Statements: 26-45
• RIDADR: UN 2811 6.1 / PGIII
• Hazardous Substances Data: 185057-00-5(Hazardous Substances Data)

Usage

General Description

Methyl 1,2,3,4-tetrahydroisoquinoline-6-carboxylate is a chemical compound, specifically an isoquinoline, that is often used in organic and medical chemistry due to its unique properties. The term "tetrahydro" indicates that the isoquinoline ring in this compound is fully saturated, meaning it has no double bonds or aromatic character. The "6-carboxylate" means there is a carboxylic acid functional group at the 6-position of this ring, which is a common motif in biologically active compounds. This group makes the compound acidic and adds potential reactivity via nucleophilic substitution reactions. Additionally, the methyl ester group aids in the compound's solubility and contributes to its reactivity.

Upstream product

• 34784-05-9 6-bromo-isoquinoline 
• 173089-82-2 isoquinoline-6-carboxylic acid methyl ester 
• 1245798-39-3 methyl 1-oxo-1,2,3,4-tetrahydroisoquinoline-6-carboxylate 
• 106778-43-2 isoquinoline-6-carboxylic acid 
• 106778-42-1 isoquinoline-6-carbonitrile 

Downstream Products

• 860457-96-1 2-(1-Phenyl-ethyl)-1,2,3,4-tetrahydro-isoquinoline-6-carboxylic acid 
• 1055948-76-9 2-cyclohexanecarbonyl-1,2,3,4-tetrahydro-isoquinoline-6-carboxylic acid methyl ester 
• 170097-66-2 3,4-Dihydro-1H-isoquinoline-2.6-dicarboxylic acid 2-tert-butyl ester-6-methyl ester 
• 170097-67-3 2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 1055947-81-3 (S)-cyclohexyl-[6-(2-pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-3,4-dihydro-1H-isoquinolin-2-yl]-methanone 
• 1055948-08-7 cyclohexyl-(6-piperidin-1-ylmethyl-3,4-dihydro-1H-isoquinolin-2-yl)-methanone 
• 1055948-77-0 2-cyclohexanecarbonyl-1,2,3,4-tetrahydro-isoquinoline-6-carboxylic acid 
• 1055948-92-9 cyclohexyl-(6-hydroxymethyl-3,4-dihydro-1H-isoquinolin-2-yl)-methanone 
• 1055948-93-0 2-cyclohexanecarbonyl-1,2,3,4-tetrahydro-isoquinoline-6-carbaldehyde 

Relevant articles and documents

Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof

The present invention relates to methods of modulating activity of histone deacetylases (HDACs). The present invention also relates to methods of treating HDAC-associated diseases including, but not limited to, cancers, inflammatory disorders, and neurode

Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation

Protein arginine methyltransferases 5 (PRMT5) represents an attractive drug target in epigenetic field for the treatment of leukemia and lymphoma. Here, a series of N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)amide derivatives targeting PRMT5 were designed with structure-based approach and synthesized. Among them, compound 46 showed potent and selective PRMT5 inhibition activity with an IC50 of 8.5 nM, which was approximately equivalent with the phase I clinical trial PRMT5 inhibitor GSK-3326595 (IC50 = 5.5 nM). Compound 46 also displayed pronounced anti-proliferative activity in MV4-11 cells (GI50 = 18 nM) and antitumor activity in MV4-11 mouse xenografts model. This molecule can serve as an excellent tool compound for probing the biological function of PRMT5.

Pyrrolo pyrimidine ring compound, its use and pharmaceutical composition (by machine translation)

The invention relates to an as TLR7 agonist of the pyrrolo pyrimidine compounds, specifically on a compound of formula (I) compound or its pharmaceutically acceptable salt, preparation method thereof, containing the compounds of the pharmaceutical composition, and its use for the preparation of antiviral drug use. Formula (I) (by machine translation)